[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

7

1 And, lastly, two last questions here. Are
2 you confusing antigens with combinations of antigens
3 and adjuvants? If you are, what is the safety record
4 of the adjuvants that are being used in the low-dose
5 products?
6 And, lastly, the medical textbooks that go
7 back maybe 20 years basically have established that
8 antibodies are pivotal in prevention of establishment
9 of infection, but the cellular immune response is
10 crucial to clearance and recovering.
11 Therefore, would you please explain the
12 relationship of this information that you've provided
13 on preexposure use of the vaccine, especially in light
14 of the information that Dr. Valentine has provided
15 showing the possibility of boosting with the patients
16 on isolate? What is the relevance of what you're
17 presenting to the post-exposure setting?
18 Those are my questions. Thank you.
19 CO-CHAIRMAN FAUCI: Larry, if you can
20 answer all of those questions within a reasonable
21 period of time? But I have a suggestion.
22 First of all, this is Frank Volvovitz, the
NEAL R. GROSS
COURT REPORTER$ AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]